JP2018521064A5 - - Google Patents

Download PDF

Info

Publication number
JP2018521064A5
JP2018521064A5 JP2018500373A JP2018500373A JP2018521064A5 JP 2018521064 A5 JP2018521064 A5 JP 2018521064A5 JP 2018500373 A JP2018500373 A JP 2018500373A JP 2018500373 A JP2018500373 A JP 2018500373A JP 2018521064 A5 JP2018521064 A5 JP 2018521064A5
Authority
JP
Japan
Prior art keywords
her2
kit
her2 antibody
cancer
bcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018500373A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018521064A (ja
JP6910339B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/041184 external-priority patent/WO2017007846A1/en
Publication of JP2018521064A publication Critical patent/JP2018521064A/ja
Publication of JP2018521064A5 publication Critical patent/JP2018521064A5/ja
Priority to JP2021112329A priority Critical patent/JP2021178825A/ja
Application granted granted Critical
Publication of JP6910339B2 publication Critical patent/JP6910339B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018500373A 2015-07-07 2016-07-06 抗ｈｅｒ２抗体−薬物複合体とｂｃｌ−２阻害剤の併用療法 Active JP6910339B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021112329A JP2021178825A (ja) 2015-07-07 2021-07-06 抗ｈｅｒ２抗体−薬物複合体とｂｃｌ−２阻害剤の併用療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562189610P 2015-07-07 2015-07-07
US62/189,610 2015-07-07
PCT/US2016/041184 WO2017007846A1 (en) 2015-07-07 2016-07-06 Combination therapy with an anti-her2 antibody-drug conjugate and a bcl-2 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021112329A Division JP2021178825A (ja) 2015-07-07 2021-07-06 抗ｈｅｒ２抗体−薬物複合体とｂｃｌ−２阻害剤の併用療法

Publications (3)

Publication Number Publication Date
JP2018521064A JP2018521064A (ja) 2018-08-02
JP2018521064A5 true JP2018521064A5 (enExample) 2019-08-08
JP6910339B2 JP6910339B2 (ja) 2021-07-28

Family

ID=56464320

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018500373A Active JP6910339B2 (ja) 2015-07-07 2016-07-06 抗ｈｅｒ２抗体−薬物複合体とｂｃｌ−２阻害剤の併用療法
JP2021112329A Pending JP2021178825A (ja) 2015-07-07 2021-07-06 抗ｈｅｒ２抗体−薬物複合体とｂｃｌ−２阻害剤の併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021112329A Pending JP2021178825A (ja) 2015-07-07 2021-07-06 抗ｈｅｒ２抗体−薬物複合体とｂｃｌ−２阻害剤の併用療法

Country Status (21)

Country Link
US (5) US10898570B2 (enExample)
EP (1) EP3319995B1 (enExample)
JP (2) JP6910339B2 (enExample)
KR (2) KR102697939B1 (enExample)
CN (2) CN107922504B (enExample)
AU (1) AU2016290065B2 (enExample)
BR (1) BR112017028012A2 (enExample)
CA (1) CA2990465A1 (enExample)
DK (1) DK3319995T3 (enExample)
ES (1) ES2731377T3 (enExample)
HR (1) HRP20191019T1 (enExample)
HU (1) HUE044139T2 (enExample)
IL (1) IL256451B (enExample)
LT (1) LT3319995T (enExample)
MX (1) MX2018000135A (enExample)
PL (1) PL3319995T3 (enExample)
PT (1) PT3319995T (enExample)
RS (1) RS58823B1 (enExample)
SI (1) SI3319995T1 (enExample)
TR (1) TR201908138T4 (enExample)
WO (1) WO2017007846A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY194408A (en) 2011-10-14 2022-11-30 Genentech Inc Uses for and Article of Manufacture Including Her2 Dimerization Inhibitor Pertuzumab
CN116531511A (zh) 2017-03-02 2023-08-04 豪夫迈·罗氏有限公司 Her2阳性乳腺癌的辅助治疗
CN107349426B (zh) * 2017-07-12 2018-03-23 马骥 阿司匹林与曲妥珠单抗联合或协同在肿瘤治疗中的应用
US12534465B2 (en) 2019-06-10 2026-01-27 Sutro Biopharma, Inc. 5H-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof
EP3980080A1 (en) * 2019-06-10 2022-04-13 Sutro Biopharma, Inc. Immunomodulator antibody drug conjugates and uses thereof
WO2024211811A2 (en) * 2023-04-05 2024-10-10 Frezent Biological Solutions, Inc. Methods and compositions for antibody-drug conjugates
CN119454975B (zh) * 2024-12-02 2025-10-21 中国医学科学院医学实验动物研究所 一种药物组合物在治疗癌症中的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2292682T3 (es) 1998-05-06 2008-03-16 Genentech, Inc. Purificacion de anticuerpos mediante cromatografia de intercambio ionico.
JP2002515511A (ja) 1998-05-15 2002-05-28 イムクローン システムズ インコーポレイティド 放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療
ES2466715T3 (es) * 1999-06-25 2014-06-11 Immunogen, Inc. Métodos de tratamiento usando conjugados de anticuerpo anti-ErbB-maitansinoide
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
PT1282443E (pt) * 2000-05-19 2009-12-04 Genentech Inc Análise de detecção génica para melhorar a probabilidade de uma resposta eficaz a uma terapia do cancro com um antagonista de erbb
US7795232B1 (en) * 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6790954B2 (en) 2002-01-29 2004-09-14 Immunogen, Inc. Mutant Actinosynnema pretiosum strain with increased maytansinoid production
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
AU2003300414A1 (en) * 2002-12-19 2004-07-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US7432088B2 (en) 2003-05-08 2008-10-07 Immunogen Inc. Methods for the production of ansamitocins
US7004206B2 (en) 2004-01-29 2006-02-28 Viken James P Automatic fluid exchanger
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
HUE035184T2 (en) * 2008-03-18 2018-05-02 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
AU2014240234B2 (en) * 2008-03-18 2016-10-06 Genentech, Inc. Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
CN102448959B (zh) 2009-05-26 2015-06-17 艾伯维巴哈马有限公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
SG184507A1 (en) * 2010-04-19 2012-11-29 Biomarker Strategies Llc Compositions and methods for prediction of drug sensitivity, resistance, and disease progression
WO2011146568A1 (en) * 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
CN107266435A (zh) * 2010-11-23 2017-10-20 Abbvie 公司 细胞凋亡诱导剂的盐和晶形
CA2835203A1 (en) * 2011-05-09 2012-11-15 University Of Virginia Patent Foundation Compositions and methods for treating cancer
KR101915942B1 (ko) * 2012-06-08 2018-11-06 에프. 호프만-라 로슈 아게 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
CN104768581A (zh) * 2012-09-07 2015-07-08 吉宁特有限公司 II型抗CD20抗体与选择性Bcl-2抑制剂的组合治疗
CN104370905B (zh) * 2014-10-22 2016-06-01 南京友杰医药科技有限公司 Bcl-2抑制剂ABT-199的合成

Similar Documents

Publication Publication Date Title
JP2018521064A5 (enExample)
JP7818502B2 (ja) 胃腸間質腫瘍を治療するためのリプレチニブ
JP2019031506A (ja) Ｔｅｃファミリーキナーゼ阻害剤アジュバント療法
Liu et al. Ultrasound-mediated destruction of paclitaxel and oxygen loaded lipid microbubbles for combination therapy in ovarian cancer xenografts
Jia et al. Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity
JP2014132009A5 (enExample)
KR20160066554A (ko) 브루톤 타이로신 키나제 억제제 및 면역요법을 이용한 치료
Cho et al. Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer
JP2012500180A5 (enExample)
JP2023022190A (ja) 癌治療
RU2638795C2 (ru) Способ введения противоопухолевого агента
KR20150132214A (ko) 방사선 직장ｓ상결장염의 치료를 위한 조성물 및 방법
JP2019530706A5 (enExample)
AU2018380174A1 (en) Use of PARP inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer
JP2020523354A5 (enExample)
HRP20191019T1 (hr) Kombinacijska terapija konjugatom protutijela i lijeka anti-her2 i inhibitorom bcl-2
CN107405316A (zh) 用于治疗原发性激素耐受性子宫内膜癌和乳腺癌的方法
JP2021505526A (ja) 少なくとも１つのスプライソソームモジュレーターと、ｂｃｌ２阻害剤、ｂｃｌ２／ｂｃｌｘｌ阻害剤及びｂｃｌｘｌ阻害剤から選択される少なくとも１つの阻害剤とを含む組合せ、並びに使用の方法
CN115803629A (zh) 使用HIF-2α抑制剂和乐伐替尼的组合治疗癌症或VON-HIPPEL LINDAU病的方法
ES2880444T3 (es) Combinación de metotrexato y simvastatina para su uso en el tratamiento del osteosarcoma
Wen et al. CTNI-12. Preliminary results of the abemaciclib arm in the individualized screening trial of innovative glioblastoma therapy (INSIGHT): a phase II platform trial using Bayesian adaptive randomization
CN111728974B (zh) 西奥罗尼用于小细胞肺癌的治疗
Chen et al. PACTO: A single center, randomized, phase II study of the combination of nab-paclitaxel and gemcitabine with or without tocilizumab, an IL-6R inhibitor, as first-line treatment in patients with locally advanced or metastatic pancreatic cancer
JP7696006B2 (ja) 化膿性汗腺炎の治療における使用のためのレミブルチニブ
JP4982377B2 (ja) 過剰増殖性疾病の治療及び予防のための組成物及び方法